RIGEL PHARMACEUTICALS INC
Current- Director 2026 to present
Executive record
Alpha ID: alpha:person:raymond-j-fureyVersion: public-0As of: 2026-09-28
Appointed EVP, General Counsel and Corporate Secretary in December 2022 and Chief Compliance Officer added in August 2023, Mr. Furey previously served as SVP and Chief Compliance Officer at Turning Point Therapeutics and Portola Pharmaceuticals, and held roles at Ara Pharmaceuticals, Mallinckrodt, Genentech, and OSI Pharmaceuticals. He holds a J.D. from Fordham University School of Law and an MBA from San Francisco State University.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
sec filing · Source published: Apr 3, 2026 · Retrieved: May 5, 2026
sec proxy · Source published: Apr 3, 2026 · Retrieved: Sep 2, 2026
sec def 14a · Source published: Apr 3, 2026 · Retrieved: Sep 12, 2026
public source · Source published: Date unavailable · Retrieved: Date unavailable
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-28